The use of whole pelvic radiotherapy (WPRT) for high-risk and lymph node-positive prostate cancer (PC) remains controversial. The purpose of this study was to evaluate the acute toxicity associated with helical tomotherapy in the treatment of high-risk and lymph node-positive prostate cancer. To do so, twenty-eight patients were treated to a dose of 54 Gy in daily fractions of 1.8 Gy to the pelvic lymph node area, while the prostate and the seminal vesicles received a simultaneous integrated boost (SIB) to a dose of 70.5 Gy. A SIB to a dose of 60 Gy was delivered to the involved lymph node region(s) in 8 patients with pelvic lymph node metastases. All patients received concurrent hormonal treatment. The incidence of grade 2 and 3 acute gastrointestinal (GI) toxicity was 7% and 0% respectively. Grade 2 and 3 acute genito-urinary (GU) side effects were observed in 14% and 4% of the patients respectively. No grade 4 side effects occurred. No increased toxicity was observed in the 8 lymph node-positive patients receiving a simultaneous pelvic nodal dose escalation. In conclusion, WPRT with a SIB to the prostate and seminal vesicles by helical tomotherapy resulted in a favourable toxicity profile. Pelvic nodal dose escalation in node-positive patients is feasible without increasing toxicity.
Introduction
The standard of care related to the use of elective and therapeutic whole pelvic radiotherapy (WPRT) in patients with high-risk and lymph node-positive prostate cancer (PC) respectively remains controversial (1) (2) (3) (4) . In patients with a high risk ( 15%) of microscopic nodal involvement, WPRT showed a trend to improved progression free survival (PFS) (5, 6) . It is not clear if conventional pelvic doses of around 45-50 Gy, as used in most of the trials, are appropriate to achieve long-term pelvic control in patients with occult and macroscopic pelvic lymph node metastases.
Today, there is no clear indication of the ideal treatment of lymph node-positive PC. Several studies indicate a possible long-term survival of patients with lymph node-positive PC undergoing hormonal treatment (HT) in combination with surgery and/or radiotherapy (RT) (4, 7-10). The timing of starting HT (immediate versus at the time of clinical progression) however does not seem to affect overall survival (11) (12) . Recent data support the use of a more aggressive approach in a subset of patients who can achieve long-term remission (13) (14) . However, toxicity of WPRT, alone or in combination with HT is not ignorable (5, (15) (16) . Recent advances in intensity modulated and image-guided RT (IMRT -IGRT) allows Technology in Cancer Research & Treatment, Volume 8, Number 5, October 2009 pelvic irradiation with a reduced toxicity to the surrounding healthy tissues (17) (18) (19) (20) . The Tomotherapy Hi-ART II system (Tomotherapy Inc., Madison, WI, USA) is a dedicated IMRT Linac, which fully integrates an inverse planning system based on collapsed cone superposition, dynamic rotational therapy and daily target localization by an integrated megavolt computed tomography (MV-CT).
The purpose of this study was to evaluate the early side effects associated with helical tomotherapy for WPRT in high-risk PC patients, in combination with a simultaneous integrated boost (SIB) to the prostate and to the involved pelvic lymph node region(s) in case of node-positive PC.
Methods

Patient Population
Between June 2007 and November 2008, 28 patients with primary locally advanced PC were consecutively treated in our department on the Tomotherapy Hi-Art II system. Eight of these patients had pelvic lymph node metastases, either clinically as determined on CT scan (5 patients) or pathologically confirmed after laparoscopic lymphadenectomy (3 patients). The other 20 patients presented with high to very high risk disease according to the NCCN risk grouping (i.e., presence of at least 1 of the following adverse factors: T3-4, Gleason 8-10, PSA > 20). The risk of microscopic pelvic nodal involvement was 15% according to the Roach equation in all patients (21) (22) . The average age was 68 years (range, 54-77 years). All patients received concurrent HT for a planned duration between 6 and 36 months. The patient characteristics are given in Table I .
Target Volumes and Margins
Irradiation of the pelvic nodal area was performed in all patients. The pelvic lymph node regions to be irradiated were: distal common iliac with the upper level at L5/S1, presacral lymph nodes (S1-S2), external and internal iliac lymph nodes and obturator lymph nodes (23). In case of node-positive PC, the involved lymph node region(s) was/were delineated as a separate clinical target volume (CTV) ( Table II. ). The prostate and the seminal vesicles (SV) were delineated in all patients. An isotropic margin of CTV to planning target volume (PTV) of 10 mm was used for the CTV of the pelvic lymph nodes, whereas CTV-PTV margins of 6, 10, and 10 mm in the laterolateral, anteroposterior and craniocaudal direction respectively were used for the PTV prostate. The bladder, rectum and loops of small bowel (from L4 to the lowest extent in the pelvis) were contoured as organs at risk (OARs).
Planning, Dose and Dose-volume Constraints
Treatment planning was performed using the integrated planning system, based on collapsed cone superposition. For all patients, a fan beam thickness (FBT) of 2.5 cm, a pitch of 0.3, and a modulation factor of 2.0-2.2 were used. The irradiation times ranged between 7-10 minutes.
A dose of 54 Gy in 30 fractions of 1.8 Gy was prescribed to the PTV lymph nodes (PTV 54Gy ). A SIB to a dose of 70.5 Gy Table I Characteristics of the 28 patients.
T stage
Gleason score Initial PSA Node status 1 (2) 2-6 (2) 3-10 (7) cN0 (20) 2 (7) 7 (14) >10-20 (10) nN1 (5) 3 (19) 8-10 (12) >20 (11) pN1 (3) NCCN = National Comprehensive Cancer Network; PSA = prostate-specific antigen. Data in parentheses are numbers of patients. Bilateral external + internal iliac 5
Bilateral external iliac 6
Bilateral external iliac 7
Bilateral obturator 8
Right obturator (2.35 Gy/fraction) was delivered to the PTV prostate and SV (PTV 70.5Gy ). In case of pelvic lymph node metastases, a pelvic nodal dose escalation to the involved pelvic region(s) was given by a SIB to a dose of 60 Gy (2 Gy/fraction) (PTV 60Gy ) ( Figure 1 ). For the PTV 54Gy and PTV 60Gy , the approach was to deliver at least 95% of the prescription dose to at least 95% of the PTV. The following rectal dose-volume constraints were considered appropriate: a maximum of 67.0 Gy (95% of the prescribed dose), the volume receiving ≥ 63.5 Gy (V 63.5Gy , 90% of the prescription dose) and the V 56.4Gy (80% of the prescription dose) were kept below 25% and 50% respectively. To meet the maximum dose of 67.0 Gy to the rectum, a PTV subvolume with a different dose prescription was defined at the interface between rectum and the PTV 70.5Gy . The dose in this overlap volume (intersection between PTV 70.5Gy and rectum) was kept at maximum 67.0 Gy (95% of the prescribed dose) by setting a hard constraint of maximum 67.0 Gy on this PTV subvolume. To obtain these dose objectives, priority ranking of the PTVs was performed in the planning optimization, with the highest priority assigned to the overlap volume. For the small bowel, the V 40Gy was kept as low as possible. The mean dose of the whole bladder was kept below 50 Gy. The overlap between bladder and PTV 70.5Gy received the prescribed dose.
Positioning and Treatment
Rectal emptying by means of a self-applied rectal enema (Microlax) was performed 1 hour before planning CT. No rectal emptying was done during the RT course. Patients were asked to empty the bladder and then to drink 500 ml of water 60 min prior to the planning CT and every treatment fraction, to obtain a reproducible bladder filling. All the patients underwent simulation and treatment in supine position. Patients were positioned on a patient support system consisting of generic carbon base plate. Knee supports, ankle cushions, and laser marks on the patient's skin were used to limit pitch and yaw rotations. Before treatment, patients underwent scanning using the tomotherapy MV-CT scan modality, and were positioned by co-registration of these images to the original kilovoltage (kV) planning CT image set (24-26). The automatic fusion algorithm was set to fuse on bony anatomy, and it allowed for correction for translations in the lateral, antero-posterior, and cranio-caudal directions and rotation in the transverse plane ("roll") (27). Exact quantification of the matching tolerances of this algorithm has been performed and reported in the literature (28). The fusion parameters were recorded and fed to the table.
Evaluation
Side effects were scored using the Radiation Therapy Oncology Group (RTOG) acute and late morbidity scoring system respectively (29), with toxicity occurring within 3 months after the initiation of RT classified as acute toxicity, chronic after. The Phoenix consensus definition "nadir + 2" was used to define biochemical failure (30). The dose-volume histograms (DVHs) were computed for the PTVs, the rectum, bladder and small bowel. The reported DVHs represent the mean, with the standard deviation (SD) plotted as a dashed line. The DVHs for rectum and bladder were calculated for the whole patient group, while for the PTVs and small bowel separately for the patients with (n = 8, boost group) and without (n = 20, no-boost group) pelvic lymph node metastases.
Results
Planning Data
In Figure 2 , the mean DVHs (± 1 SD) of the PTVs, rectum, bladder and small bowel are shown. The mean PTV 70.5Gy dose was 69.8 ± 1.0 Gy and 70.0 ± 0.6 Gy for the no-boost and boost group respectively. Considering the PTV 54Gy , 95% of the prescribed dose was delivered to 98.9 ± 1.0% and 98.6 ± 1.3% in the no-boost and boost group respectively. In the boost group, 99.4 ± 0.6% of the PTV 60Gy received 95% of the prescribed dose. Note the tail of the PTV 54Gy reflecting the dose gradient from the PTV 54Gy to the PTV 70.5Gy and PTV 60Gy.
For the small bowel, the V 40Gy was 83.2 ± 56.5 cc and 93.5 ± 94.8 cc for the no-boost and boost group respectively. The mean volumes of small bowel lying in the pelvis were 525.7 ± 444.1 cc and 501.0 ± 313.2 cc for the no-boost and boost group respectively. The wide SD of the small bowel DVH is caused by the highly variable volume of small bowel lying in the pelvis in the different patients.
Considering the rectum, the V 67.0Gy was 1.6 ± 2.0%. The V 63.5Gy and V 56.4Gy were 23.1 ± 13.3% and 45.9 ± 17.0% respectively. The mean bladder dose for the whole patient group was 46.9 ± 6.9 Gy.
Acute Toxicity
All patients finished their RT course without interruptions of toxicity reasons. No grade 3 or 4 acute gastrointestinal (GI) side effects were observed. Two patients (7%) developed grade 2 acute GI toxicity, both grade 2 proctitis. In one patient (4%), pre-existing prostate hypertrophia resulted in a grade 3 acute genito-urinary (GU) toxicity with urinary obstruction. Four patients (14%) developed grade 2 acute GU toxicity. Most occurring urinary symptoms were pollakiuria and urgency. Six patients (21%) presented acute upper GI toxicity, all grade 1 nausea. No skin toxicity was observed. For the patients receiving a pelvic nodal dose escalation up to 60 Gy, only grade 1 acute GU and GI toxicity was observed. Table III lists the incidence of acute toxicities.
Follow Up
With a median follow up of 10 months (range, 3-19 months), grade 2 late GU toxicity was observed in 1 patient (4%). Eight patients (29%) developed grade 1 late GU toxicity. For late digestive chronic toxic effects, 3 (11%) and 2 (7%) patients developed grade 1 and 2 late GI toxicity respectively. Until now, two patients experienced grade 2 rectal blood loss. No late grade 3 toxicity was observed and one patient presented biochemical failure with the presence of bone metastases. However, median follow up is too short to draw conclusions for late toxicity and tumor control outcome.
Discussion
The presence of microscopic pelvic lymph node metastases is common in high-risk PC patients. For these patients, it can be argued that definitive RT of the prostate without WPRT may be an inadequate treatment. Based on the results from a prospective randomized trial comparing WPRT with prostate-only RT (RTOG 94-13), a trend to improved PFS was demonstrated in patients with a risk of lymph node involvement more than 15% receiving WPRT (5, 6). However, no consistent improvement in patient outcome has been shown with the use of WPRT (31-34). Whether this is due to inefficient doses to the pelvic lymph nodes (range between 40 and 50 Gy EQD2 in the WPRT series) or the unavoidable synchronous presence of distant metastases in these patients, is not clear. One can argue that higher doses are needed for these patients to achieve pelvic control, while others associate the presence of nodal metastases to incurable disease.
The experience of combining HT with WPRT in lymph nodepositive PC is limited. Recently, some studies have indicated a potential long survival in a subset of patients with lymph node positive PC treated with a combination of HT with locoregional treatment (surgery and/or RT) (13-14). Goldner et al., reported a 5-and 8-year survival rate of 78 and 67% respectively in patients with lymph node-positive PC treated by a multimodality approach (13). Recently, Da Pozzo et al., showed excellent long-term outcome for node-positive PC patients treated with radical surgery and adjuvant HT ± RT(14). The number of involved lymph nodes and extent of lymph node invasion is an important prognostic factor (13) (14) 35) . Goldner et al., reported long term relapse-free survival in patients with only 1 or 2 lymph node metastases (13). Unfortunately, a randomized phase III trial (RTOG 96-08) comparing HT versus HT plus definitive external beam irradiation for pathologic lymph node-positive PC was closed because of poor accrual.
Use of advanced RT treatment techniques such as IMRT-IGRT can create high conformal dose distributions, with a steep dose fall-off between the PTV and OARs, resulting in a favourable toxicity profile (17) (18) (19) (20) (36) (37) . Recently, the clinical and dosimetric feasibility of helical tomotherapy for the treatment of the pelvic nodal area in PC was reported (18) (19) . Toxicity is in line with the data of the present study, confirming the feasibility of helical tomotherapy for WPRT while escalating the dose to the prostate. The incidence of grade 2 acute GU and GI toxicity was 14% and 7% respectively. In comparison, the patients receiving 3D-conformal pelvic irradiation in the RTOG 94-13 protocol had 31% and 47% grade 2 acute GU and GI toxicity respectively (5, 16 HT and RT (38, 40) . Although the very small number of node-positive patients receiving a SIB to a dose of 60 Gy to the involved lymph node region(s) and the short follow up, this appeared not to result in increased acute GI or GU toxicity. This concept of pelvic nodal dose escalation is not widely explored. One can argue, as in line with other locally advanced cancers, that nodal dose escalation is indispensable for effective eradication of involved lymph nodes. Hong et al., reported the dosimetric and clinical feasibility of 56 Gy in 2 Gy/fraction to the pelvic lymph nodes with conformal avoidance-based IMRT (43) .
The present study shows that helical tomotherapy allows delivery of a SIB to the primary tumor and the involved lymph node regions without increasing acute toxicity and the irradiated volume of small bowel. Today, no long term results are available with regard to pelvic nodal dose escalation in node-positive PC. Phase III trials should be conducted to evaluate the real clinical effect of pelvic nodal dose escalation in the multimodality treatment approach of node-positive PC patients.
Conclusion
WPRT with a SIB to the prostate by helical tomotherapy offers a favourable early toxicity profile. Pelvic nodal dose escalation is feasible in node-positive PC without increased acute toxicity. Longer follow up for evaluation of clinical outcome and late toxicity is required to be certain of the safety of WPRT with SIB by IMRT-IGRT in the treatment of lymph node-positive PC.
